Explore AOD-9604 dosage trends, reconstitution volumes, and vial preferences based on real-world WPA calculator data from peptide researchers.
AOD-9604, a stabilized fragment of human growth hormone (hGH 177–191), is typically researched at mcg-level doses. This data reveals the dose amounts, vial sizes, and bacteriostatic water volumes researchers most commonly select when setting up their AOD-9604 reconstitution protocol.
AOD-9604 is one of the more interesting "what could have been" stories in modern peptide research. The molecule was developed by Metabolic Pharmaceuticals, an Australian biotech that engineered it as a stabilized version of the C-terminal hGH fragment 177-191 — the short, lipolytic tail of human growth hormone first characterized in the 1990s as the region of the molecule that retains hGH's fat-mobilizing activity without its IGF-1-driven growth-promoting effects. The preclinical work was unusually compelling for an obesity peptide.
AOD-9604 is a growth-hormone-fragment research peptide most often sourced for fat-loss and body-composition protocols, sometimes stacked with a GLP-1 agonist. It ships as a lyophilized powder you reconstitute with bacteriostatic water before use.
Animal data suggest AOD-9604 stimulates lipolysis and inhibits lipogenesis in adipose tissue, apparently through a non-classical β3-adrenergic-receptor pathway distinct from the metabolic and IGF-1 effects of full-length hGH. The molecule does not appear to elevate IGF-1 or to activate the GH receptor in the way intact hGH does.
Human work on AOD-9604 has been limited: a published safety and tolerability study in humans demonstrated an acceptable side-effect profile, and Metabolic Pharmaceuticals advanced an oral formulation into Phase 2 for obesity before the program failed to meet its weight-loss endpoints and was discontinued in 2007. Pre-clinical lipolysis activity was first characterized in obese mice. Subsequent investigator interest has shifted toward cartilage and tendon repair models, though no published Phase 2/3 musculoskeletal trials exist.
AOD-9604 has a reported half-life of ~30 min, and the dose intervals researchers model most often fall around once daily (morning fasted). Very short half-life — each dose is gone within a few hours and there is no buildup between days. Timing relative to fasting and meals matters more than steady-state level. It is catalogued under Weight Loss on WPA.
799 AOD-9604 reconstitution calculations have been logged by the WPA community. The most common dose entered is 300mcg (213 calculations). The most common bacteriostatic water volume is 2mL. The most popular vial size is 5mg (518 sessions). The most common dosing frequency is daily (7x/week) (64 logged protocols), followed by once weekly (24).
These figures come from anonymized WPA peptide calculator sessions.
All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.